Inflammatory bowel disease (IBD) is a group of diseases characterized by chronic and recurrent inflammation of the gastrointestinal tract. The incidence of IBD has increased significantly in past decades. The aim of this study is to review the literature on the possibility of using fecal calprotectin in the diagnosis of inflammatory bowel disease, the assessment of the severity of the disease, the prediction of a relapse and the monitoring of remission. The literature review was conducted using the PubMed and Google Scholar databases. Most of the publications included in the study are from 2013 or later. Laboratory, imaging, endoscopic and histopathological tests are used in the diagnosis of IBD. In order to confirm the diagnosis, an endoscopic examination with the collection and evaluation of histopathological specimens is required. Laboratory tests useful in the diagnosis of non-specific inflammations include non-specific tests such as the white blood cells count, ESR and CRP. Faecal calprotectin is a protein complex produced by neutrophils in the inflamed gut. The studies included in this review have shown the presence of increased levels of fecal calprotectin in patients with relapses in the course of inflammatory bowel disease. Accordingly, determination of this marker may be useful in the diagnosis of chronic abdominal pain and as screening prior to colonoscopy.
Download full-text PDF |
Source |
---|
Pharmaceutics
January 2025
Department of Pharmacy, "Federico II" University of Naples, 80131 Naples, Italy.
Arginase (ARG) is a binuclear manganese-containing metalloenzyme that can convert L-arginine to L-ornithine and urea and plays a key role in the urea cycle. It also mediates different cellular functions and processes such as proliferation, senescence, apoptosis, autophagy, and inflammatory responses in various cell types. In mammals, there are two isoenzymes, ARG-1 and ARG-2; they are functionally similar, but their coding genes, tissue distribution, subcellular localization, and molecular regulation are distinct.
View Article and Find Full Text PDFNutrients
January 2025
Research Unit for Dietary Studies at The Parker Institute, Bispebjerg and Frederiksberg Hospital, 2000 Frederiksberg, Denmark.
Background: Diet significantly impacts the onset and progression of inflammatory bowel disease (IBD), and diet offers unique opportunities for treatment and preventative purposes. However, despite growing interest, no diet has been conclusively associated with improved long-term clinical and endoscopic outcomes in IBD, and evidence-based dietary guidelines for IBD remain scarce. This narrative review critically examines dietary assessment methods tailored to the unique needs of IBD, highlighting opportunities for precision and inclusivity.
View Article and Find Full Text PDFNutrients
January 2025
Department of Gastroenterology and Hepatology, University Medical Centre Groningen (UMCG), 9713 GZ Groningen, The Netherlands.
To assess nutritional intake of patients with inflammatory bowel disease (IBD), a disease-specific food frequency questionnaire (FFQ) was developed: the Groningen IBD Nutritional Questionnaire (GINQ-FFQ). Aim of this study was to assess the relative validity of the GINQ-FFQ. Between 2019 and 2022, participants of the 1000IBD cohort were included and filled out a 3-day food diary and the GINQ-FFQ.
View Article and Find Full Text PDFNutrients
January 2025
College of Veterinary Medicine, Gansu Agricultural University, Lanzhou 730070, China.
Background/objectives: Ulcerative colitis (UC) is a chronic and easily recurrent inflammatory bowel disease. The gut microbiota and plasma metabolites play pivotal roles in the development and progression of UC. Therefore, therapeutic strategies targeting the intestinal flora or plasma metabolites offer promising avenues for the treatment of UC.
View Article and Find Full Text PDFPharmaceuticals (Basel)
January 2025
Department of Pharmaceutical Analysis, Faculty of Pharmacy and Biochemistry, University of Zagreb, 10000 Zagreb, Croatia.
Background/objectives: Janus kinase inhibitors open new horizons for small-molecule drugs in treating inflammatory bowel disease, with ritlecitinib demonstrating significant efficacy in clinical trials for ulcerative colitis and Crohn's disease. Ritlecitinib, a second-generation JAK3 inhibitor, is a novel therapeutic agent for alopecia areata and other autoimmune conditions.
Methods: A new stability-indicating UHPLC-DAD-MS/MS method was developed, validated, and applied for a forced degradation study of ritlecitinib under ICH guidelines.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!